Clinical Research Directory

Inclusion Criteria: * Age :18 Years to 75 Years; * ECOG physical score 0-2 points; expected survival time ≥ 1 year; * Pathologically confirmed diagnosis with Stage III NSCLC which harbored ALK fusion detected by next generation sequencing (NGS) or immunohistochemistry (IHC) with or without FISH. Suspected N2 (station 2/4/7) for stage III disease should be confirmed by either mediastinoscopy or EBUS. * At least one measurable target lesion according to the RECIST 1.1 standard; * The main organ function meets the following criteria: 1) blood routine: absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 / L, hemoglobin ≥ 80 g / L; 2) blood biochemistry: total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal; * Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up. Exclusion Criteria: * Stage I, stage II and metastatic stage IV NSCLC; * Histologically confirmed small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer); * Patients who have previously used any other anti-tumor drugs or received surgery/radiotherapy; * Patients with any underlying disease that investigators consider it may affect patient's prognosis including sever cardiovascular, pulmonary disease or serious infections. * Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy; * Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures; * Patients with low compliance or willingness to take the drugs and surveillance.